首页> 外文OA文献 >Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion
【2h】

Cord Blood-Derived Hematopoietic Stem/Progenitor Cells: Current Challenges in Engraftment, Infection, and Ex Vivo Expansion

机译:脐血来源的造血干/祖细胞:植入,感染和体内扩增的当前挑战。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Umbilical cord blood has served as an alternative to bone marrow for hematopoietic transplantation since the late 1980s. Numerous clinical studies have proven the efficacy of umbilical cord blood. Moreover, the possible immaturity of cells in umbilical cord blood gives more options to recipients with HLA mismatch and allows for the use of umbilical cord blood from unrelated donors. However, morbidity and mortality rates associated with hematopoietic malignancies still remain relatively high, even after cord blood transplantation. Infections and relapse are the major causes of death after cord blood transplantation in patients with hematopoietic diseases. Recently, new strategies have been introduced to improve these major problems. Establishing better protocols for simple isolation of primitive cells and ex vivo expansion will also be very important. In this short review, we discuss several recent promising findings related to the technical improvement of cord blood transplantation.
机译:自1980年代后期以来,脐带血已替代骨髓用于造血移植。大量的临床研究已证明脐带血的功效。此外,脐带血中细胞的可能不成熟为HLA失配的接受者提供了更多选择,并允许使用来自无关供体的脐带血。然而,即使在脐血移植后,与造血系统恶性肿瘤相关的发病率和死亡率仍然保持较高水平。感染和复发是造血系统疾病患者脐带血移植后死亡的主要原因。最近,引入了新的策略来改善这些主要问题。建立简单的原始细胞分离和离体扩增的更好协议也将非常重要。在这篇简短的评论中,我们讨论了一些与脐血移植技术改进有关的近期有希望的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号